筋萎縮性側索硬化症の世界市場：地域別の分析・予測 (2025-2035年)

ALS（筋萎縮性側索硬化症）に対する認知の高まり、遺伝子研究の進展、ALSを標的とする治療薬の開発パイプラインの拡大により、市場は成長を遂げています。

ALSは運動ニューロン侵す進行性の神経変性疾患であり、科学の進歩に伴い、治療法もより標的を絞った効果的なものへと進化しつつあります。

筋萎縮性側索硬化症は、脳および脊髄における運動ニューロンの進行性変性を特徴とし、その結果として筋力低下、身体機能障害、最終的には死に至る疾患です。その分子的メカニズムを解明しようとする研究が進む中で、革新的な治療ソリューションが次々と登場しています。その結果、ALS治療市場は今、治療選択肢の大きな転換点を迎えようとしています。

市場のライフサイクルステージ

ALS治療市場は現在、急速に進化している段階にあり、これまでの対症療法中心の治療から、疾患の進行を修飾する標的治療へとシフトしつつあります。現時点では、ALSの進行を遅らせ、症状を緩和することを目的とした治療が中心ですが、疾患の遺伝的・分子的メカニズムに着目した新たな介入法が登場し始めています。具体的には、疾患修飾療法（DMT）、遺伝子治療、バイオ医薬品といったアプローチが、ALS治療の在り方を大きく変える可能性を秘めています。

北米は、世界のALS市場において依然として主要なシェアを占める地域であると予測されています。これは、整備された医療インフラ、高い診断率、ALS研究への多額の投資によるものです。大手製薬企業、研究機関、医療提供者がこの地域でALS治療の進展に注力しており、市場のさらなる拡大が見込まれます。

当レポートでは、世界の筋萎縮性側索硬化症の市場を調査し、主要動向、市場影響因子の分析、法規制環境、臨床試験の動向、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

第1章 世界の筋萎縮性側索硬化症市場：業界の展望

• 市場概要とエコシステム
• 筋萎縮性側索硬化症の疫学的分析
  • 米国
  • EU5カ国
• 市場動向
• 臨床試験
  • フェーズ別
• 規制状況分析
  • 米国の法的要件と枠組み
  • EUにおける法的要件と枠組み
• 市場力学
  • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第2章 世界の筋萎縮性側索硬化症市場：地域別

• 北米
  • 主な調査結果
  • 市場力学
  • 市場規模・予測
• 欧州
  • 主な調査結果
  • 市場力学
  • 市場規模・予測
• アジア太平洋
  • 主な調査結果
  • 市場力学
  • 市場規模・予測

第3章 世界の筋萎縮性側索硬化症市場：競合ベンチマーキングと企業プロファイル

• 競合情勢
  • 各社の主要戦略と展開
  • 主な展開の分析
• 企業プロファイル
  • Mitsubishi Tanabe Pharma Corporation
  • Biogen Inc.
  • Aquestive Therapeutics, Inc.
  • Ionis Pharmaceuticals
  • MediciNova
  • AB Science
  • Brainstorm-Cell Therapeutics
  • Italfarmaco S.p.A.

第4章 調査手法

List of Figures

• Figure: Global Amyotrophic Lateral Sclerosis Market, Coverage
• Figure: Global Amyotrophic Lateral Sclerosis Market, Key Trends, Impact Analysis
• Figure: Global Amyotrophic Lateral Sclerosis Market, Competitive Landscape, January 2022- April 2025

List of Tables

• Table: Global Amyotrophic Lateral Sclerosis Market, Dynamics and Impact Analysis
• Table: Global Amyotrophic Lateral Sclerosis Market, Regulatory Landscape
• Table: Global Amyotrophic Lateral Sclerosis Market, (by Region), $Million, 2023-2035

Global Amyotrophic Lateral Sclerosis Market: Overview

The increasing awareness of ALS, advancements in genetic research, and a growing pipeline of therapeutic drugs targeting ALS are driving the market's growth. ALS is a progressive neurodegenerative disease affecting motor neurons, and with the advancements in science, the treatment landscape is becoming increasingly targeted and effective.

Amyotrophic lateral sclerosis is characterized by the progressive degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, disability, and eventually, death. With significant research efforts aimed at understanding its molecular mechanisms, innovative therapeutic solutions are emerging. As a result, the amyotrophic lateral sclerosis market is on the cusp of a breakthrough in terms of treatment options.

Market Lifecycle Stage

The market for amyotrophic lateral sclerosis treatments is in a rapidly evolving phase, shifting from symptomatic management toward more targeted therapies aimed at modifying the disease progression. While current treatments mainly focus on slowing the progression of amyotrophic lateral sclerosis and providing symptomatic relief, newer interventions are beginning to explore the genetic and molecular mechanisms underlying the disease. Disease-modifying therapies (DMTs), gene therapies, and biologic agents hold the potential to significantly alter the treatment landscape for amyotrophic lateral sclerosis patients.

North America is expected to maintain its dominant position in the global amyotrophic lateral sclerosis market, driven by a well-established healthcare infrastructure, a high rate of diagnosis, and substantial investment in amyotrophic lateral sclerosis research. Major pharmaceutical companies, research institutions, and healthcare providers are focused on advancing treatment options for amyotrophic lateral sclerosis in the region, which is expected to drive further market expansion.

Demand - Drivers and Limitations

The global amyotrophic lateral sclerosis market is driven by several key factors:

• Rising prevalence of amyotrophic lateral sclerosis cases will drive market demand
• Advances in genetic research, coupled with improved understanding of the molecular mechanisms involved in amyotrophic lateral sclerosis
• An increase in clinical trials and investments will accelerate the development of innovative treatments for amyotrophic lateral sclerosis

Limitations:

• The high cost of amyotrophic lateral sclerosis treatments may limit accessibility and market growth
• Lack of awareness in emerging markets will hinder the adoption of amyotrophic lateral sclerosis treatments

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: This report provides valuable insights for pharmaceutical companies and biotech firms looking to develop new amyotrophic lateral sclerosis treatments, focusing on genetic therapies, precision medicine, and biologics that target amyotrophic lateral sclerosis-specific molecular pathways. It helps identify emerging trends and the potential for breakthrough therapies that can modify disease progression.

Competitive Strategy: Pharmaceutical companies and healthcare providers can use the information in this report to evaluate the current competitive landscape, assess market trends, and develop strategies that ensure long-term success in the global amyotrophic lateral sclerosis Market. Understanding the major players, new entrants, and their strategies will help companies stay ahead of the competition.

Key Market Players and Competition Synopsis

The companies profiled in this report are selected based on expert insights, evaluating company coverage, product portfolio, and market penetration. Leading players in the global amyotrophic lateral sclerosis market include pharmaceutical companies who hold substantial shares of the market.

Some of the prominent names established in this market are:

• Mitsubishi Tanabe Pharma Corporation
• Biogen Inc.
• Aquestive Therapeutics, Inc.
• Ionis Pharmaceuticals
• MediciNova
• AB Science
• Brainstorm-Cell Therapeutics
• Italfarmaco S.p.A.

Table of Contents

Executive Summary

Scope of Study

Definition

Inclusion and Exclusion Criteria

1. Global Amyotrophic Lateral Sclerosis Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis of Amyotrophic Lateral Sclerosis
  • 1.2.1 U.S.
  • 1.2.2 EU5
• 1.3 Market Trends
• 1.4 Clinical Trials
  • 1.4.1 By Phase
• 1.5 Regulatory Landscape Analysis
  • 1.5.1 Legal Requirement and Framework in U.S.
  • 1.5.2 Legal Requirement and Framework in E.U.
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Amyotrophic Lateral Sclerosis Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 France
      • 2.2.3.1.3 Italy
      • 2.2.3.1.4 U.K.
• 2.3 Asia-Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis Market (by Country)
      • 2.3.3.1.1 Japan

3. Global Amyotrophic Lateral Sclerosis Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Mitsubishi Tanabe Pharma Corporation
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Key Personnels
    • 3.2.1.5 Analyst View
  • 3.2.2 Biogen Inc.
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers / End Users
    • 3.2.2.4 Key Personnels
    • 3.2.2.5 Analyst View
  • 3.2.3 Aquestive Therapeutics, Inc.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers / End Users
    • 3.2.3.4 Key Personnels
    • 3.2.3.5 Analyst View
  • 3.2.4 Ionis Pharmaceuticals
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers / End Users
    • 3.2.4.4 Key Personnels
    • 3.2.4.5 Analyst View
  • 3.2.5 MediciNova
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers / End Users
    • 3.2.5.4 Key Personnels
    • 3.2.5.5 Analyst View
  • 3.2.6 AB Science
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers / End Users
    • 3.2.6.4 Key Personnels
    • 3.2.6.5 Analyst View
  • 3.2.7 Brainstorm-Cell Therapeutics
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers / End Users
    • 3.2.7.4 Key Personnels
    • 3.2.7.5 Analyst View
  • 3.2.8 Italfarmaco S.p.A.
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers / End Users
    • 3.2.8.4 Key Personnels
    • 3.2.8.5 Analyst View

4. Research Methodology